⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823529 | 1.00 | — | — | |
| SCHEMBL515943 | 1.00 | — | — | |
| SCHEMBL28734819 | 0.96 | — | — | |
| Iodide SCHEMBL16859450 | 0.96 | — | — | |
| SCHEMBL10408865 | 0.96 | — | — | |
| SCHEMBL10410198 | 0.96 | — | — | |
| Rubidium SCHEMBL10408863 | 0.96 | — | — | |
| SCHEMBL10408857 | 0.96 | — | — | |
| SCHEMBL10408925 | 0.96 | — | — | |
| SCHEMBL10410225 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |
| WO-2014106019-A2 | NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION | PHILADELPHIA HEALTH & EDUCATION CORPORATION, D/B/A DREXEL (US) | 2014-07-03 | — | — | WO | disclosed |
| US-20080262083-A1 | ANTIBACTERIAL AGENTS | IDEXX LABORATORIES, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7402697-B2 | chloramphenicols; e.g. D-(threo)-1-p-methylsulfonyl-2-amino-3-fluoro-1-propanol(\"Fenicol Compounds\"); antibiotics; veterinary medicine; side effect reducion | IDEXX LABORATORIES INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1836162-A2 | ANTIBACTERIAL AGENTS | IDEXX Laboratories Inc (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007058639-A2 | ANTIBACTERIAL AGENTS | IDEXX LABORATORIES INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20060047138-A1 | Antibacterial agents | IDEXX LABORATORIES INC. | 2006-03-02 | — | — | US | disclosed |